Integra LifeSciences Holdings Corp. (NASDAQ:IART)‘s stock had its “outperform” rating reaffirmed by investment analysts at Oppenheimer Holdings Inc. in a research report issued on Wednesday. They presently have a $93.00 target price on the stock. Oppenheimer Holdings Inc.’s price objective indicates a potential upside of 12.75% from the company’s current price.

Other analysts have also issued research reports about the company. Jefferies Group reissued a “buy” rating and set a $95.00 price objective on shares of Integra LifeSciences Holdings Corp. in a report on Tuesday, September 27th. Argus lifted their price objective on Integra LifeSciences Holdings Corp. from $90.00 to $105.00 and gave the stock a “buy” rating in a report on Friday, September 23rd. Zacks Investment Research raised Integra LifeSciences Holdings Corp. from a “hold” rating to a “buy” rating and set a $85.00 price objective on the stock in a report on Tuesday, June 28th. Barclays PLC lifted their price objective on Integra LifeSciences Holdings Corp. from $77.00 to $84.00 and gave the stock an “equal weight” rating in a report on Friday, July 29th. Finally, TheStreet lowered Integra LifeSciences Holdings Corp. from a “buy” rating to a “hold” rating in a report on Friday, September 30th. Four investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $88.25.

Integra LifeSciences Holdings Corp. (NASDAQ:IART) traded up 0.13% on Wednesday, hitting $82.59. The stock had a trading volume of 93,939 shares. Integra LifeSciences Holdings Corp. has a 1-year low of $54.75 and a 1-year high of $88.86. The firm’s 50-day moving average price is $85.62 and its 200-day moving average price is $77.24. The firm has a market cap of $3.09 billion, a P/E ratio of 341.28 and a beta of 0.43.

Integra LifeSciences Holdings Corp. (NASDAQ:IART) last announced its quarterly earnings data on Thursday, July 28th. The company reported $0.79 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.76 by $0.03. Integra LifeSciences Holdings Corp. had a return on equity of 15.41% and a net margin of 0.79%. The company had revenue of $249.30 million for the quarter, compared to analyst estimates of $243.17 million. During the same quarter last year, the firm earned $0.79 EPS. Integra LifeSciences Holdings Corp.’s revenue for the quarter was up 17.2% compared to the same quarter last year. On average, equities research analysts predict that Integra LifeSciences Holdings Corp. will post $3.48 earnings per share for the current year.

In other news, VP Richard D. Gorelick sold 4,000 shares of the business’s stock in a transaction on Monday, August 1st. The stock was sold at an average price of $84.60, for a total transaction of $338,400.00. Following the completion of the sale, the vice president now owns 9,702 shares in the company, valued at $820,789.20. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Peter J. Arduini sold 24,009 shares of the business’s stock in a transaction on Tuesday, August 9th. The stock was sold at an average price of $84.52, for a total value of $2,029,240.68. Following the sale, the chief executive officer now owns 29,602 shares of the company’s stock, valued at approximately $2,501,961.04. The disclosure for this sale can be found here. 22.00% of the stock is owned by company insiders.

Large investors have recently added to or reduced their stakes in the company. Mason Street Advisors LLC purchased a new stake in Integra LifeSciences Holdings Corp. during the second quarter worth $453,000. Amalgamated Bank increased its stake in Integra LifeSciences Holdings Corp. by 15.2% in the second quarter. Amalgamated Bank now owns 3,478 shares of the company’s stock worth $292,000 after buying an additional 460 shares during the last quarter. Legal & General Group Plc increased its stake in Integra LifeSciences Holdings Corp. by 7.3% in the second quarter. Legal & General Group Plc now owns 6,735 shares of the company’s stock worth $531,000 after buying an additional 457 shares during the last quarter. Metropolitan Life Insurance Co. NY increased its stake in Integra LifeSciences Holdings Corp. by 1.7% in the second quarter. Metropolitan Life Insurance Co. NY now owns 21,577 shares of the company’s stock worth $1,721,000 after buying an additional 351 shares during the last quarter. Finally, Arizona State Retirement System increased its stake in Integra LifeSciences Holdings Corp. by 2.0% in the second quarter. Arizona State Retirement System now owns 15,047 shares of the company’s stock worth $1,200,000 after buying an additional 300 shares during the last quarter. Institutional investors own 88.32% of the company’s stock.

Integra LifeSciences Holdings Corp. Company Profile

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing and marketing of surgical implants and medical instruments. Its products are used in neurosurgery, extremity reconstruction, orthopedics and general surgery. Its segments include Specialty Surgical Solutions, which offers products, including specialty surgical instrumentation for a range of specialties.

5 Day Chart for NASDAQ:IART

Receive News & Stock Ratings for Integra LifeSciences Holdings Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences Holdings Corp. and related stocks with our FREE daily email newsletter.